NVIDIA And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI
By Amit Chowdhry ● Yesterday at 6:04 PM
NVIDIA and Eli Lilly and Company said they will jointly invest up to $1 billion over five years to launch a new AI co-innovation lab aimed at tackling persistent bottlenecks in pharmaceutical R&D, from early discovery through development and, longer term, manufacturing and supply chain optimization. The companies unveiled the initiative around the J.P. Morgan Healthcare Conference, positioning the effort as a combined push to pair Lilly’s drug discovery, clinical, and manufacturing expertise with NVIDIA’s accelerated computing stack and life sciences AI platforms.